Kisspeptin 112-121

Phase 2

SStephanie B. Seminara, MD

Kisspeptin 112-121 is one of 11 therapeutic programs targeting Reproductive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Reproductive DisorderRecruiting

AmenorrheaRecruiting

Hypogonadotropic HypogonadismRecruiting

Reproductive DisorderPhase 1

Recruiting

AmenorrheaPhase 2

Recruiting

Hypogonadotropic HypogonadismPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Amenorrhea

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

2 2

Zometa

Pfizer

Phase 3

1 3

Romosozumab

Amgen

Phase 3

1 4

Cytotec

Pfizer

Preclinical

1 5

Kisspeptin 112-121

SStephanie B. Seminara, MD

Phase 2

1 6

Kisspeptin

MMassachusetts General Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Hypogonadotropic Hypogonadism

NCT05896293

Q2 2030

Phase 2Recruiting

Amenorrhea

NCT07224438

Phase 1Recruiting

Reproductive Disorder

NCT07224490

Clinical

Trials by Indication[1]

Hypogonadotropic Hypogonadism2 trials

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Completed·SStephanie B. Seminara, MD·Phase 2·NCT04648969·18 enrolled

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT05896293·36 enrolled

Amenorrhea1 trial

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT07224438·20 enrolled

Reproductive Disorder1 trial

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Recruiting·SStephanie B. Seminara, MD·Phase 1·NCT07224490·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Kisspeptin 112-121. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Kisspeptin 112-121. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stephanie B. Seminara, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SStephanie B. Seminara, MD

Kisspeptin 112-121

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2030

Trials by Indication[1]

Hypogonadotropic Hypogonadism2 trials

Amenorrhea1 trial

Reproductive Disorder1 trial

References

Drug Info

Quick Facts

Related News